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Abstract
Background: Trials which test the effectiveness of interventions compared with the status quo frequently encounter
challenges. The cohort multiple randomised controlled trial (cmRCT) design is an innovative approach to the design
and conduct of pragmatic trials which seeks to address some of these challenges.
Main text: In this article, we report our experiences with the first completed randomised controlled trial (RCT) using
the cmRCT design. This trial—the Depression in South Yorkshire (DEPSY) trial—involved comparison of treatment as
usual (TAU) with TAU plus the offer of an intervention for people with self-reported long-term moderate to severe
depression. In the trial, we used an existing large population-based cohort: the Yorkshire Health Study. We discuss our
experiences with recruitment, attrition, crossover, data analysis, generalisability of results, and cost. The main challenges
in using the cmRCT design were the high crossover to the control group and the lower questionnaire response rate
among patients who refused the offer of treatment. However, the design did help facilitate efficient and complete
recruitment of the trial population as well as analysable data that were generalisable to the population of interest.
Attrition rates were also smaller than those reported in other depression trials.
Conclusion: This first completed full trial using the cmRCT design testing an intervention for self-reported depression
was associated with a number of important benefits. Further research is required to compare the acceptability and
cost effectiveness of standard pragmatic RCT design with the cmRCT design.
Trial registration: ISRCTN registry: ISRCTN02484593. Registered on 7 Jan 2013.
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Background
Since its publication in 2010, a number of studies have
started using the innovative cohort multiple randomised
controlled trial (cmRCT) design [1], also known as
‘Trials within Cohorts’ (www.twics.global). The cmRCT
design uses a large observational cohort of people with
the condition of interest, with regular measurement of
outcomes for the whole cohort. This cohort provides a
capacity for multiple randomised controlled trials
(RCTs) over time. For each RCT, routine cohort data
help to identify those eligible for the trial. Eligible partic-
ipants are then randomly selected to be offered the trial
intervention, and their outcomes are compared with
those not randomly selected (i.e., those receiving usual
care). Like some cluster trial designs, the cmRCT design
uses a ‘randomisation without prior consent’ approach
to informed consent [2]; thus, information about the
intervention is provided only to the intervention group,
and this information is given after (not before)
randomisation.
Researchers in a variety of settings (including hospital,
primary care and community) in the United Kingdom,
Canada and The Netherlands use the design [3], includ-
ing a number of studies testing interventions for mental
health in the United Kingdom [4, 5] and Canada [6]. In
this article, we report on our experiences of using the
cmRCT design in relation to recruitment, attrition,
crossover, data analysis, cost and generalisability of
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results for the first completed full-scale RCT of the
cmRCT design: the Depression in South Yorkshire
(DEPSY) trial. In this trial, we used an existing cohort to
compare treatment as usual (TAU) with TAU plus the
offer of a course of treatment provided by a homeopath
for patients with self-reported long-term moderate to
severe depression.
Main text
Recruitment
Trials often struggle to reach recruitment goals on time,
and many trials fail entirely to recruit a sufficient num-
ber of participants [7], especially trials in depression [8].
This is also true for pragmatic trials of interventions
such as counselling and cognitive behavioural therapy
for depression [9–11]. Consequences of insufficient
recruitment include at best reduced power and/or
extended recruitment periods, contributing to increased
costs, and at worst inability to draw conclusions because
of underpowered trials and wasted resources.
Recruitment to the DEPSY trial was from an estab-
lished population-based cohort (the Yorkshire Health
Study; www.yorkshirehealthstudy.org [12]) set up to
facilitate multiple pragmatic trials using the cmRCT
design. All people in the cohort had previously provided
self-reported information on their health (including
anxiety or depression), health-related behaviours and
health care resource use, and had given consent to be
contacted again. The researchers invited those who had
reported long-term depression or feeling moderately or
severely anxious or depressed when completing the
Yorkshire Health Study questionnaire (n = 5740), to
complete a detailed mood and health questionnaire.
Completed questionnaires were returned by 2214
patients (38.6%). This provided the trial researchers with
the information needed to apply the inclusion/exclusion
criteria, as well as baseline information for the trial. All
cohort patients had given permission for their data to be
used to look at the benefit of health treatments and to
be contacted again by the researchers. Additionally,
written informed consent was requested by patients
taking up the offer of treatment.
It took a total of 5 months for 566 eligible participants
(17% more than the original sample size calculation) to
be recruited to the DEPSY trial [13]. The method used
avoided many recruitment barriers encountered in other
trials, where clinicians may struggle to find time to
recruit patients, feel reluctant to let the research disrupt
consultations, or consider the randomisation process to
be inappropriate and the research process to be too
much of a burden for patients [8–10, 14].
The majority of people take part in trials in the hope
that they will obtain direct and/or indirect benefits for
themselves or others as a result of their participation
(e.g., improved health) [15]. It is common for patients to
refuse randomisation because of the risk of not being of-
fered the treatment of their preference [8, 16]. The use
of the cmRCT design avoided this barrier because only
those randomly selected to receive an offer of treatment
were informed about the intervention being tested [1].
All 185 patients in the ‘Offer’ group were sent a letter of-
fering them the treatment, 150 of whom were reached
by telephone. About half (n = 95, 51.4%) accepted the
offer of treatment. Everyone in both the ‘Offer’ and ‘No
offer’ groups were sent baseline and follow-up question-
naires, unless they asked not to be sent any further
questionnaires (n = 62, 11.0%).
Attrition
Patients who agree to participate in trials may be disap-
pointed if they are not allocated to receive their pre-
ferred intervention [17]. As a consequence, they may
become uncooperative, report poorer outcomes than ex-
perienced and even leave the trial, which may in turn
significantly affect analyses and the interpretation of re-
sults [18]. Such attrition may lead to biased results and,
at worst, inability to draw conclusions [19].
The fact that patients in the TAU control arm were
unaware of the intervention being trialled may have con-
tributed to lowering attrition rates (attrition here refers
to non-completion of follow-up questionnaires at 6 and
12 months). Following discussion with other mental
health researchers, it was estimated that a realistic re-
sponse rate would be 60% [13]. Results showed that
more than 80% returned completed questionnaires at
6 months, and 67% returned them at 12 months. When
considering drop-out for treatment among those who
accepted the offer of treatment in the offer group, over
90% followed their treatment with several consultations.
Other researchers have found attrition rates of, for ex-
ample, 16% for psychotherapy and 32% for parenting
education [20]. Researchers in trials of antidepressant
treatment found attrition rates of 23% at 6 months and
47% at 12 months [21].
The rate at which people completed follow-up
questionnaires was lower (68%) in the group randomly
selected to receive the offer of the intervention (Offer
group), compared with the control group (87%), where
patients were not offered the intervention (No offer
group). In trials using the cmRCT design, some patients
in the Offer group may be uninterested in responding to
questionnaires if they either have no interest in or dislike
the intervention [18]. This will not be an issue for
patients in the No offer group, because they are unaware
of the intervention. It could therefore explain a between
group difference in questionnaire response rates.
Within the Offer group, 88% of those who accepted
the offer and received treatment returned the completed
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questionnaire (equal to the response rate in the control
group), compared with only 54% of those who did not
take up the offer (non-accepters). To understand what
might have contributed to these differences, baseline
characteristics of the four groups (Offer and No offer
group responders and non-responders at 6 and
12 months) were compared using a multiple linear
regression model for each baseline covariate, as recom-
mended by Walters [22]. There was no evidence of
significant differences between the four groups in regard
to their depression or anxiety scores or in any other
baseline covariates considered to be likely to influence
outcomes. Between-group comparisons could therefore
be carried out with limited risk of significant influence
of known potential confounding factors.
Although there were no known characteristics that
could explain a lower return rate of questionnaires in
Offer group non-accepters, the question remains why
this particular group was less likely to return ques-
tionnaires. One possible explanation could be that
non-accepters upon receiving follow-up questionnaires
thought that their response was not needed, because
they had not taken up the offer of treatment. More-
over, patients who do not believe in the intervention
or who have unsuccessfully tried it in the past may
not be interested in participating in the trial, which
was reported by two patients in this trial. Further
research is required to understand non-response in
trials using the cmRCT design.
Crossover and data analysis
Patients in pragmatic trials not randomly selected to re-
ceive their preferred intervention may seek the interven-
tion outside the trial, thereby contributing to bias
resulting from crossover [23]. Van der Velden et al. [18]
suggested there is little risk of crossover from the con-
trol group when using the cmRCT design, because pa-
tients in the control group are not given information
about the intervention being trialled. We collected data
on patients’ use of interventions (including the treat-
ment used in this trial) and did not find any cases of
crossover from the control to the intervention arm. A
bigger challenge in the cmRCT design is ‘crossover’ from
the intervention to the control arm by patients not
accepting the intervention being offered and remaining
on TAU. In the DEPSY trial, 40% took up the offer of
treatment and received treatment; thus, 60% crossed
over to the control group. This has implications for the
analysis of results.
Using an intention-to-treat (ITT) analysis when sig-
nificant proportions cross over, results in ‘watered-down’
estimates of potentially effective interventions [24, 25].
Such crossover is to be expected in trials using the
cmRCT design [18]. Per-protocol analyses are often used
by researchers as an additional (or in some cases as the
only) analysis, but this approach carries a risk of bias.
For the DEPSY trial, we used an ITT analysis to esti-
mate the effect of the offer of treatment, as well as an
instrumental variables analysis [26], which is a type of
complier average causal effect analysis that takes into
account baseline values and where randomisation is the
instrument [25], to assess the effectiveness of treatment
received. This analysis compares Offer group patients
who have received the intervention with patients in the
No offer group who would have received the interven-
tion if they had been offered it. This analytic method has
been recommended as the secondary analysis used in
RCTs because it carries lower risk of bias than per-
protocol or on-treatment analyses [25].
Generalisability of results
The aim of pragmatic trials is to produce results which
are generalisable to the relevant clinical population.
Therefore, whenever possible, the intervention should be
provided in a way that is comparable to regular practice to
a trial population that is comparable to the population of
interest, and the information provided (and consents
sought) also should be as similar as possible. It is not com-
mon in real-world practice to give patients information
about interventions that they cannot receive. Commonly,
available treatment options are discussed, and treatment
plans are agreed with patients. The standard procedure
for RCTs is that treatment is decided by chance, and infor-
mation is not tailored to the individual patient but is gen-
eric, regardless of whether the patient is offered the
treatment. In trials with the cmRCT design, only those
randomly selected to be offered the intervention are
provided with information about the intervention. Hence,
patients in the No offer group are not informed about
interventions they cannot receive. This is more compar-
able to real-world practice and contributes therefore to
increasing the generalisability of results.
The seven practitioners delivering the intervention had
been instructed to practice in the normal manner.
Therefore, as in everyday practice, no treatment proto-
cols were provided for them, other than guidelines for
how to deal with risk issues and adverse events. There-
fore, the frequency and length of consultations, as well
as the medications and advice given, were comparable to
routine practice.
Analysis of the self-reported data showed that the
DEPSY trial participants had several similarities to the
general population of patients with depression. Depres-
sion was significantly correlated to commonly seen
comorbidities (anxiety and obesity), a greater chance of
being unemployed [27] and deprived [28] than the
general population, and with a larger proportion of
women [29] (further details in trial article). Patients
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more commonly had chronic depression and depression
was not diagnosed but was self-reported using the
Patient Health Questionnaire (PHQ-9). The PHQ-9 has
been found to have a high degree of validity, reliability,
sensitivity and specificity, and it is sensitive to change
and useful for patients with a variety of comorbidities
[30]. Though not intended to replace diagnostic inter-
views, it has been found to be more conservative than
clinician-rated outcomes [31]. The results of the trial are
in many respects therefore more likely to be generalis-
able to the population of patients with chronic self-
reported moderate to severe depression.
Cost
Recruitment to the trial via the Yorkshire Health Study
cohort cost £15,000 (access to the cohort, researcher
time, and printing and mailing out questionnaires and
letters), which equates to £26.50 per participant
recruited. Identifying and recruiting participants from a
large cohort then enabled the DEPSY trial to use
unequal randomisation (1:2 intervention to control).
This meant that (compared with 1:1 randomisation) 25%
fewer patients were offered the intervention, thus
reducing the trial intervention costs by £10,000.
Conclusion
The main benefits of using the cmRCT design to test an
intervention for self-reported depression were full, fast
and efficient recruitment; lower attrition rates than other
depression trials; and a trial population broadly similar
to the general population of patients self-reporting
chronic moderate to severe depression. The main chal-
lenges in using the cmRCT design for this pragmatic
RCT were the lower follow-up (questionnaire response)
rate in those who refused the offer of the intervention
and the large ‘crossover’ (60%) from the intervention to
the control group. The data nevertheless allowed us to
carry out an ITT analysis for the offer of treatment and
also to assess the effectiveness of treatment received
using an instrumental variables analysis. Further re-
search is required to compare the acceptability and cost-
effectiveness of a standard pragmatic RCT design with
the cmRCT design for research in all fields of healthcare,
including mental health.
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